Ad-hoc
Announcements

Disclosure of an inside information according to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)

LR HEALTH & BEAUTY SE REACHES AN AGREEMENT WITH BONDHOLDERS AND SHAREHOLDER REGARDING A COMPREHENSIVE RESTRUCTURING OF THE 2024/2028 BOND – EUR 20 MILLION IN NEW CAPITAL AND SIGNIFICANTLY REDUCED DEBT STRUCTURE

Ahlen, 11 February 2026 – Today, LR Health & Beauty SE (the “Company”) reached an agreement with bondholders representing more than two thirds (2/3) of the nominal amount of the Company’s outstanding 2024/2028 bonds (ISIN: NO0013149658) (the “Bonds”) as well as the Company’s shareholder regarding a comprehensive restructuring of the Bonds and the Company’s capital structure. 
The restructuring comprises an aggregate equity and debt injection of EUR 20 million in new capital, consisting of a (i) EUR 10 million equity contribution and (ii) EUR 10 million in New Money Senior Bonds (as defined below). The shareholder Evoco will continue its commitment to the Company demonstrating confidence and support to the Company.
The Company’s debt structure will be significantly downsized and restructured as follows:

• Senior secured debt of EUR 62.5 million comprising of the following tranches which will rank pari passu with each other and carry a fixed cash interest of 6.75% per annum:
  • EUR 10 million new money senior bonds (the “New Money Senior Bonds”), to be subscribed for in cash by bondholders (offered pro rata to all bondholders). The New Money Senior Bond issue will be fully backstopped by certain major bondholders.
  • EUR 20 million reinstated elevated bonds (the “Reinstated Elevated Bonds”), allocated pro rata to bondholders who participate in the New Money Senior Bonds.
  • EUR 32.5 million reinstated bonds (the “Reinstated Bonds”), allocated pro rata to all existing bondholders. 
• Unsecured subordinated junior bonds of EUR 27.5 million (the “Junior Bonds”), allocated pro rata to all existing bondholders, with payment-in-kind interest stepping up linearly from 6% per annum year one to 10% per annum year five, maturing in 2031. 
• The part of the nominal amount of the Bonds (including accrued interest thereunder) that is not reinstated into Reinstated Elevated Bonds, Reinstated Bonds or Junior Bonds shall be written off in its entirety.

The agreement is set out in a lock-up agreement entered into between the Company, its shareholder and bondholders representing more than two thirds (2/3) of the nominal amount for the Bonds, whereunder inter alia the parties have undertaken to implement the comprehensive restructuring and the bondholders have agreed to not accelerate the Bonds during the lock-up period (ending 30 April 2026). Implementation of the restructuring is subject to approval by bondholders in one or several written procedures and by formal shareholder approval, and shall be completed by the end of the lock-up period.

IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de 

End of inside information

Disclosure of an inside information according to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)

LR HEALTH & BEAUTY SE: PRELIMINARY RESULTS FOR FINANCIAL YEAR 2025 / TARGETED EQUITY CONTRIBUTION / TARGETED RESTRUCTURING OF THE 2024/2028 BONDS

Ahlen, 23 January 2026 – Today, based on the preliminary financial results for the financial year 2025, the Management Board of LR Health & Beauty SE (the “Company”) expects an EBITDA* reported of around EUR 16 million for the financial year 2025 (previously expected to be between EUR 17.0 million and EUR 20.0 million). At the same time, the Management Board of the Company expects sales (revenue from goods sold) of around EUR 277 million for the full year 2025 (previously expected to be between EUR 276 million and EUR 281 million). 

Also today, EY-Parthenon announced the completion of a draft IDW S 6 restructuring opinion in respect of the Company. Pursuant to the analysis set out in that draft restructuring opinion, the Company will for the financial year 2028 achieve an EBITDA* of EUR 27.3 million and sales of EUR 281.5 million in the sensitivity case, and an EBITDA* of EUR 31.4 million as well as sales of EUR 284.7 million in the management case.

Against this background, the Company decided today to enter into discussions with its shareholder and with the bondholders of the Company’s outstanding 2024/2028 bonds (ISIN: NO0013149658) (the “Bonds”). The aim of such discussions is to explore the possibility of a financial restructuring of the Company comprising (the following measures together the “Restructuring Measures”):

• an equity contribution from the Company’s shareholder in the amount of EUR 10 million for financing of the Company’s operating business; and 
• bondholder approval of certain amendments to the terms and conditions of the Bonds (through a new written procedure under the Bonds) in respect of:
  • a write-down of 55 % of the nominal amount of the Bonds on a pro rata basis (including the capitalised interest in respect of the interest payments under the Bonds due in November 2025 and February 2026), after which the outstanding nominal amount under the Bonds will amount to EUR 61.3 million;
  • an extension of the term of the Bonds until 31 December 2029;
  • a deferral of the interest payments under the Bonds due in November 2025 and February 2026 (on a capitalising basis and subject to write-down mechanism set out above) and other interest payments under the Bonds due during the period up to and including May 2027 (on a capitalising basis) until the Bonds’ extended maturity date;
  • cash sweep mechanisms for excess cash over a EUR 15 million threshold; and
  • a contractual right (Besserungsschein) for the bondholders to receive cash in an aggregate amount of up to EUR 74.9 million (being equal to the written down amount) out of any excess cash received out of a refinancing of the Bonds.

The holders of the Bonds shall be entitled to participate in the refinancing process.
If the Restructuring Measures cannot be implemented, it is currently assumed that the holders of the Bond could expect an insolvency quota of around 6% in an insolvency liquidation scenario. 

IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de 

*EBITDA, based on IFRS as used in the unaudited consolidated interim report of the Company for Q3 2025 which can be found on the Company’s website at https://media.lrworld.com/IR/Interim_Report_Q3_2025.pdf.

End of inside information

Ad-hoc Announcements - LR Health & Beauty SE | 2025-11-25 |  6.30 p.m.

Disclosure of an inside information according to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)

LR HEALTH & BEAUTY SE RECEIVES SUPPORTING VOTING INTENTIONS BY 69.57% OF THE ADJUSTED NOMINAL AMOUNT FOR TEMPORARY WAIVERS UNDER THE 2024/2028 BONDS 

Ahlen, 25 November 2025 – Today, LR Health & Beauty SE (the “Company”) was informed that bondholders representing approximately 69.57% of the adjusted nominal amount of the Company’s 2024/2028 bonds (ISIN: NO0013149658) (the “Bonds”) had expressed their intention to vote in favour of the temporary waivers, relating to postponement of interest payments and non-compliance with the maintenance test (including the leverage covenant) for a period up to and including 28 February 2026, that were requested in the written procedure initiated by the Company on 14 November 2025 under the terms and conditions of the Bonds (the “Written Procedure”). 

Under the Written Procedure, a quorum of at least 50% of the adjusted nominal amount of the Bonds and a voting majority of at least 66.67% (two-thirds majority) of the adjusted nominal amount of the holders of the Bonds participating in the Written Procedure is required. Deadline for voting is 15:00 hrs CET on 28 November 2025.

For further information regarding the Written Procedure, please refer to the notice of the written procedure which is accessible on the Company’s website at https://ir.lrworld.com/en/bond/.

IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de 

End of inside information

Ad-hoc Announcements - LR Health & Beauty SE | 2025-10-20 |  8.17 p.m.

Disclosure of an inside information according to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)

BREACH OF LEVERAGE COVENANT / NO INTEREST PAYMENT / STANDSTILL NEGOTIATIONS WITH AN AD HOC GROUP OF BONDHOLDERS / APPOINTMENT OF A REPUTABLE FIRM TO SUPPORT A FINANCIAL RESTRUCTURING

Ahlen, 20 October 2025 – LR Health & Beauty SE (the “Company”) announced on 28 August 2025, that it intended to initiate discussions with the holders (the “Bondholders”) of the 2024/2028 bonds (ISIN: NO0013149658) (the “Bonds”) regarding a potential breach of the leverage covenant requiring the Company to maintain a ratio of net debt to EBITDA[1] of 4.50:1 as at 30 September 2025 (the “Leverage Covenant”).

Today, the board of the Company identified a breach of the Leverage Covenant and decided to enter into discussions with an ad hoc group of Bondholders with the objective to enter into a standstill undertaking. Furthermore, the Company decided to prioritize operations in the interest of all stakeholders and to defer interest payments. The standstill undertaking shall therefore comprise, inter alia, that Bondholders shall not derive any rights from the breach of the Leverage Covenant and from a non-payment of interest. The purpose of the standstill undertaking is  to provide the Company with sufficient time to complete the assessment of the current situation and establish an appropriate action plan for the Company.

In light of the above, the board of the Company also decided today that a reputable firm shall be appointed to prepare a restructuring opinion to support the negotiations with the Bondholders and to identify appropriate measures in relation to its capital and financing structure in order to sustainably improve the group’s current financial position and to also provide for investment capacity.

IR contact:

cometis AG

Thorben Burbach

Unter den Eichen 7 | Gebäude D

65195 Wiesbaden

Phone: +49(0)611 - 205855-23

Fax: +49(0)611 - 205855-66

E-mail: burbach@cometis.de

Disclosure of an inside information acc. to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)

LR Health & Beauty SE: Potential breach of Leverage Covenant as at 30 September 2025 – Management Board intends to enter into discussions with bondholders of the 2024/2028 bond regarding a precautionary resolution on a waiver of compliance with the Leverage Covenant as at 30 September 2025 and an amendment to the bond terms; adjustment of EBITDA guidance for the financial year 2025. 

Ahlen, 28 August 2025 – The Management Board of LR Health & Beauty SE (“LR” or the “Company”) resolved today to initiate precautionary negotiations with the holders of the 2024/2028 bond (ISIN: NO0013149658) concerning a proposal to amend the bond terms. The background to this decision is a potential breach by the Company of the covenant under Clause 13.2 of the bond terms, pursuant to which the Company must ensure that net debt in relation to EBITDA does not exceed the threshold of 4.50:1 as at 30 September 2025 (“Leverage Covenant”). Clause 13.2.1 (iii) of the bond terms provides that the Leverage Covenant decreases from 4.75:1 to 4.50:1 with effect from 1 July 2025. Based on the valuation and calculation information currently available, though still preliminary in nature, the Management Board assumes that compliance with the Leverage Covenant on the review date of 30 September 2025 is unlikely. This is due to EBITDA developing less favourably than expected, primarily attributable to increased or increasing costs in the areas of marketing and sales.

The Management Board has therefore resolved to enter into precautionary negotiations with the bondholders regarding an amendment to the bond terms – in particular the Leverage Covenant – and, if necessary, to request their consent to a waiver of the Leverage Covenant as at 30 September 2025. Furthermore, the Management Board will in due course provide information on the further course of action concerning the nature and timing of any vote on an amendment to the bond terms.

Furthermore, the Management Board of the Company is adjusting the guidance for the  financial year 2025 published on 25 April 2025. With regard to sales (revenue from goods sold), the Management Board now expects a stable development compared with the previous year. Previously, stable to moderately increasing sales had been forecast. EBITDA for the 2025 financial year is now expected to range between EUR 24.0 million and EUR 27.0 million – whereas the previous guidance anticipated significant EBITDA growth compared with the prior-year figure of EUR 27.3 million. The revision of the guidance is essentially due to increased or increasing costs in the areas of marketing and sales. This trend also continued in July, leading the Management Board to conclude that the previous guidance is unlikely to be achieved through catch-up effects or cost-saving measures.

IR Contact: 
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
phone: +49(0)611 - 205855-23
fax: +49(0)611 - 205855-66
email: burbach@cometis.de

End of inside information

Disclosure of an inside information acc. to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR) 

Change in the Management Board of LR Health & Beauty SE

Ahlen, 21 July 2025 – The Supervisory Board of LR Health & Beauty SE, issuer of the bond (ISIN: NO0013149658, German Securities Code (WKN): A3513A), has decided to appoint Mr. Jörg Körfer to the Management Board with effect from August 1, 2025. At the same time, Dr. Andreas Laabs and Andreas Grootz will leave the Management Board by mutual agreement on 31 July 2025.
 

IR contact:

cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone.: +49(0)611 – 205855-23
Fax: +49(0)611 – 205855-66
E-Mail: burbach@cometis.de


End of inside information

Disclosure of an inside information acc. to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)

Ahlen, 26 November 2024 – In the third quarter of 2024 LR Health & Beauty SE (bond, ISIN NO0013149658) increased sales (revenue from goods sold) by 7.2% to EUR 69.4 million (Q3 2023: EUR 64.7 million). Accordingly, sales in the first nine months of 2024 totaled EUR 212.7 million (9M 2023: EUR 205.6 million). In the third quarter of 2024 EBITDA reported amounted to EUR 7.3 million (Q3 2023: EUR 7.1 million). For the first nine months of 2024 EBITDA reported thus totaled EUR 19.0 million (9M 2023: EUR 22.4 million).  
 
Based on the business results for the first nine months of 2024 and the realignment of the career plan for distributors in the third quarter of 2024, LR Health & Beauty SE is adjusting its forecast for sales and EBITDA reported for the full year 2024. LR Health & Beauty SE is increasing the sales guidance for the 2024 financial year and now expects sales to range in a corridor of EUR 288 million to EUR 292 million. Management originally assumed that sales (revenue from goods sold) would be at the previous year's level (2023: EUR 276.5 million). The company is also adjusting its earnings expectations for 2024 and revising its forecast for EBITDA reported to be in the range of EUR 26 million to EUR 29 million. Originally, management expected a slightly lower to stable EBITDA figure year-on-year (2023: EUR 31.4 million). The underlying reason is that the realignment of the career plan for partners in the third and fourth quarters of 2024 will lead to a significant increase in distributors, which will have a positive impact on sales development. At the same time, the result is burdened by refinancing costs incurred and, above all, by one-off, extraordinary effects in the low single-digit million euro range due to changes to the distributors' career plan.   

IR contact: 
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone.: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-Mail: burbach@cometis.de

End of inside information

NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, CYPRUS, HONG KONG, ITALY, JAPAN, NEW ZEALAND, SOUTH AFRICA, THE UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ANY FURTHER MEASURES FROM LR GLOBAL HOLDING GMBH, LR HEALTH & BEAUTY SE, PARETO SECURITIES AS, FRANKFURT BRANCH, ARCTIC SECURITIES AS OR ANY OTHER PARTY. 

Disclosure of an inside information acc. to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)

LR GLOBAL HOLDING GMBH GIVES NOTICE OF CONDITIONAL VOLUNTARY TOTAL REDEMPTION OF ITS OUTSTANDING 2021/2025 BONDS AND LR HEALTH & BEAUTY SE ISSUES NEW SENIOR SECURED BONDS OF EUR 130 MILLION 

Ahlen, 19 February 2024 – LR Global Holding GmbH (the “Company”) gives conditional notice of voluntary total redemption of its outstanding EUR 125 million senior secured 2021/2025 bonds with ISIN NO0010894850 (the “Existing Bonds”) in full and announces that the Company’s parent company LR Health & Beauty SE has, following a successfull book building process, placed new senior secured bonds with ISIN NO0013149658 due in 2028 with a nominal amount of EUR 130 million (the ”New Bonds”) and generating proceeds of approximately EUR 125 million. 

A notice of a conditional voluntary total redemption of the Existing Bonds will be sent to Verdipapirsentralen ASA (Euronext Securities Oslo) (“VPS”) for delivery to persons registered in the securities account with VPS as holders of Existing Bonds. 

The redemption is conditional upon successful settlement of the New Bonds and the receipt of the proceeds from the New Bonds by the Company from a designated escrow account prior to the lapse of 7 March 2024 (the “Condition”). Should the Condition not be fulfilled by the lapse of 7 March 2024, the redemption will not occur (unless the Condition has been waived by the Company at its sole discretion) which will, in such case, be communicated by the Company through a subsequent announcement. 

Subject to the fulfilment or waiver of the Condition, the date for redemption is set at 11 March 2024 and the record date for the redemption will be 7 March 2024, i.e. two business days prior to the redemption date. The Existing Bonds will then be redeemed at an amount equal to 101.45 % of the total outstanding nominal amount (i.e., EUR 1,014.50 per Existing Bond) together with any unpaid interest accrued until but excluding the redemption date.

In connection with the redemption, the Existing Bonds will be delisted from Frankfurt Stock Exchange and Nasdaq Stockholm.
The New Bonds will have a term of 4 years and will carry a floating rate coupon of 3 months EURIBOR plus 7.5 % per annum. The Company intends to apply for admission to trading of the Bonds on the Open Market of the Frankfurt Stock Exchange and the corporate bond list of Nasdaq Stockholm. 

This announcement is for information purposes only and is not to be construed as an offer to purchase or sell or a solicitation of an offer to purchase or sell with respect to any securities of the Company or LR Health & Beauty SE.

IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de

This information is information that LR Global Holding GmbH is obliged to make public pursuant to the EU Market Abuse Regulation (EU 596/2014). The information in this publication has been made public through the agency of the responsible person set out above for publication at the time stated by the Company's news distributor, EQS Group AG, at the time of publication.

Important Note
THE SECURITIES MENTIONED HEREIN HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE US SECURITIES ACT. THEY MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT. NO PUBLIC OFFERING WILL BE MADE IN THE UNITED STATES AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER TO SELL NOR A SOLICITATION TO BUY OR SUBSCRIBE FOR SECURITIES OF LR GLOBAL HOLDING GMBH AND/OR LR HEALTH & BEAUTY SE AND NO EXCHANGE OFFER IS BEING MADE IN THE UNITED STATES, AUSTRALIA, CANADA, CYPRUS, HONG KONG, ITALY, JAPAN, NEW ZEALAND, SOUTH AFRICA, THE UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION/SUCH OFFER WOULD REQUIRE ANY FURTHER MEASURES FROM LR GLOBAL HOLDING GMBH, LR HEALTH & BEAUTY SE, PARETO SECURITIES AS, FRANKFURT BRANCH, ARCTIC SECURITIES AS OR ANY OTHER PARTY OR BE PROHIBITED BY APPLICABLE LAW.
 

NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, CYPRUS, HONG KONG, ITALY, JAPAN, NEW ZEALAND, SOUTH AFRICA, THE UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ANY FURTHER MEASURES FROM LR GLOBAL HOLDING GMBH, LR HEALTH & BEAUTY SE, PARETO SECURITIES AS, FRANKFURT BRANCH, ARCTIC SECURITIES AS OR ANY OTHER PARTY. 

Disclosure of an inside information acc. to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)

LR GLOBAL HOLDING GMBH ANNOUNCES ITS INTENTION TO EXERCISE THE CALL-OPTION TO REDEEM ITS OUTSTANDING 2021/2025 BONDS SUBJECT TO A SENIOR SECURED BOND ISSUANCE BY LR HEALTH & BEAUTY SE WITH A TARGET VOLUME OF EUR 125 MILLION 

Ahlen, 13 February 2024 – LR Global Holding GmbH (the “Company”) announces that the Company contemplates a refinancing of the Company’s outstanding EUR 125,000,000 senior secured 2021/2025 bonds with ISIN NO0010894850 (the “Existing Bonds”), subject to an issue of a new senior secured corporate bond under Swedish law (Nordic Bond) with a target volume of EUR 125,000,000 (the ”New Bonds”) by the Company’s parent company LR Health & Beauty SE. 

LR Health & Beauty SE has mandated Pareto Securities AS, Frankfurt Branch and Arctic Securities AS as joint bookrunners to arrange credit investor meetings in connection with the issue of the New Bonds. A capital markets transaction may follow, subject to market conditions. 

Subject to the successful issuance of the New Bonds and the receipt of the required net proceeds from such issuance, the Company intends to mainly use these proceeds to exercise its call-option and redeem in full the EUR 125,000,000 outstanding amount of its Existing Bonds. In accordance with the terms and conditions, the Existing Bonds due 2025 would be redeemed at a redemption price of 101.45 %, plus accrued and unpaid interest thereon up to, but excluding, the redemption date. 

This announcement is not a redemption notice in accordance with the terms and conditions of the Existing Bonds, and such redemption notice will be given by the Company only upon a successful placement of the New Bonds on the basis of a book-building process. 

IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de 

This information is information that LR Global Holding GmbH is obliged to make public pursuant to the EU Market Abuse Regulation (EU 596/2014). The information in this publication has been made public through the agency of the responsible person set out above for publication at the time stated by the Company's news distributor, EQS Group AG, at the time of publication.

Important Note
THE SECURITIES MENTIONED HEREIN HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE US SECURITIES ACT. THEY MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT. NO PUBLIC OFFERING WILL BE MADE IN THE UNITED STATES AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER TO SELL NOR A SOLICITATION TO BUY OR SUBSCRIBE FOR SECURITIES OF LR GLOBAL HOLDING GMBH AND/OR LR HEALTH & BEAUTY SE AND NO EXCHANGE OFFER IS BEING MADE IN THE UNITED STATES, AUSTRALIA, CANADA, CYPRUS, HONG KONG, ITALY, JAPAN, NEW ZEALAND, SOUTH AFRICA, THE UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION/SUCH OFFER WOULD REQUIRE ANY FURTHER MEASURES FROM LR GLOBAL HOLDING GMBH, LR HEALTH & BEAUTY SE, PARETO SECURITIES AS, FRANKFURT BRANCH, ARCTIC SECURITIES AS OR ANY OTHER PARTY OR BE PROHIBITED BY APPLICABLE LAW.
 

Disclosure of an inside information acc. to Article 17 of the Regulation (EU) No 596/2014

Dr. Andreas Laabs becomes new chairman of the management board of the LR Group as successor for Andreas Friesch

Ahlen, 23 May 2022 – LR Global Holding GmbH ("Company") as the issuer of the bonds (WKN: A3H3FM / ISIN: NO0010894850) informs about the fact that Dr. Andeas Laabs, currently CFO and COO of the Company, will become the new chairman of the management board of LR Health & Beauty SE as well as CEO of the Company. The current chairman of the management board, Andreas Friesch, will for personal reasons by mutual agreement resign as chairman of the management board of LR Health& Beauty SE as well as managing director/CEO of the Company and will leave the LR Group on 27 May 2022.

IR Contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Building D
65195 Wiesbaden
Tel.: +49 (0)611 - 205855-23
Fax: +49 (0)611 - 205855-66
E-Mail: burbach@cometis.de